Key result
SARS-CoV-2 infection promotes neuroinflammation and thrombosis, driving risk of stroke and neurodegenerative disease.
Answers are grounded in this paper and cite their sources.
Review reveals how SARS-CoV-2 drives neuroinflammation and vascular damage, exacerbating multiple sclerosis, ischemic stroke, and Alzheimer's disease progression.
In 2024, over 775 million cases of COVID-19 were recorded, including approximately 7 million deaths, indicating its widespread and dangerous nature. The disease is caused by the SARS-CoV-2 virus, which can manifest a wide spectrum of symptoms, from mild infection to respiratory failure and even death. Neurological symptoms, such as headaches, confusion, and impaired consciousness, have also been reported in some COVID-19 patients. These observations suggest the potential of SARS-CoV-2 to invade the central nervous system and induce neuroinflammation during infection. This review specifically explores the relationship between SARS-CoV-2 infection and selected neurological diseases such as multiple sclerosis (MS), ischemic stroke (IS), and Alzheimer's disease (AD). It has been observed that the SARS-CoV-2 virus increases the production of cytokines whose action can cause the destruction of the myelin sheaths of nerve cells. Subsequently, the body may synthesize autoantibodies that attack nerve cells, resulting in damage to the brain's anatomical elements, potentially contributing to the onset of multiple sclerosis. Additionally, SARS-CoV-2 exacerbates inflammation, worsening the clinical condition in individuals already suffering from MS. Moreover, the secretion of pro-inflammatory cytokines may lead to an escalation in blood clot formation, which can result in thrombosis, obstructing blood flow to the brain and precipitating an ischemic stroke. AD is characterized by intense inflammation and heightened oxidative stress, both of which are exacerbated during SARS-CoV-2 infection. It has been observed that the SARS-CoV-2 demonstrates enhanced cell entry in the presence of both the ACE2 receptor, which is already elevated in AD and the ApoE ε4 allele. Consequently, the condition worsens and progresses more rapidly, increasing the mortality rate among AD patients. The above information underscores the numerous connections between SARS-CoV-2 infection and neurological diseases.
No takes yet. Share an insight, caveat, or question.
Kryńska et al. (2024) conducted a review in COVID-19 and neurological diseases (multiple sclerosis, ischemic stroke, and Alzheimer's disease). SARS-CoV-2 infection was evaluated on Development and progression of multiple sclerosis, ischemic stroke, and Alzheimer's disease. SARS-CoV-2 infection promotes neuroinflammation, demyelination, and thrombosis, contributing to the onset or progression of multiple sclerosis, ischemic stroke, and Alzheimer's disease.
Synapse has enriched 10 related papers. Consider them for comparative context: